stars 1 stars 2 stars 3

FIBROTX is a privately held company founded in November 2005. Our company is providing innovative tools for personalized dermatology and skin care. FibroTx is housed in state-of-the-art laboratory and prototype-manufacturing facilities at the Tallinn Science Park Tehnopol, Estonia. OUR RESEARCH TEAM consists of highly competent and qualified professionals. We have extensive experience in biomarker research and assay development. OUR MISSION is to develop, manufacture and market non-invasive skin diagnostic devices based on proprietary technologies (patents pending): Transdermal Analysis Patch (TAP): A highly versatile research and development tool for multiplex analyses of protein-based biomarkers on skin. TAP is being offered to customers as a fee-for-service skin diagnostic tool. Skin Exploratory Lateral Flow (SELF): A skin diagnostic device for multiplex analyses of biomarkers from skin for specialists and home use.

FibroTx Questions

The FibroTx annual revenue was $5 million in 2026.

Toomas Neuman is the Chief Scientific Officer of FibroTx.

1 people are employed at FibroTx.

The NAICS codes for FibroTx are [54, 541, 5417, 541713, 54171].

The SIC codes for FibroTx are [873, 87].

Top FibroTx Employees

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users